Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$65.82 MLiabilities$454.59 MNon-current liabilities$388.78 MCurrent assets$653.79 MAssets$701.69 MEquity$247.10 MGross equity(calculated)$1.21 BNon-current assets$47.90 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSShort-term investmentsCash and cash equivalentsPrepaid expenses and other current assetsLong-term investmentsOther non-current assetsOperating lease right-of-use assets, netProperty and equipment, netAccrued expensesAccounts payableOperating lease liabilities, currentConvertible senior notes, netRoyalty obligationSenior secured term loan, netOperating lease liabilities, less current portionAdditional paid-in capitalCommon stock, par value $0.0001 per share; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 63,330,747 and 54,485,518 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive lossCurrent liabilitiesCurrent liabilities$65.82 MAccrued expensesAccrued expenses$57.41 MAccounts payableAccounts payable$7.59 MLiabilitiesLiabilities$454.59 MOperating lease liabilities, currentOperating lease liabilities, current$823.00 KNon-current liabilitiesNon-current liabilities$388.78 MConvertible senior notes, netConvertible senior notes, net$222.96 MCurrent assetsCurrent assets$653.79 MRoyalty obligationRoyalty obligation$91.74 MAssetsAssets$701.69 MSenior secured term loan, netSenior secured term loan, net$74.06 MEquityEquity$247.10 MShort-term investmentsShort-term investments$446.55 MOperating lease liabilities, less current portionOperating lease liabilities, less current portion$22.00 KGross equity (calculated)Gross equity(calculated)$1.21 BCash and cash equivalentsCash and cash equivalents$196.58 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$10.67 MLong-term investmentsLong-term investments$30.76 MNon-current assetsNon-current assets$47.90 MOther non-current assetsOther non-current assets$16.29 MAdditional paid-in capitalAdditional paid-in capital$1.21 BOperating lease right-of-use assets, netOperating lease right-of-use assets, net$821.00 KProperty and equipment, netProperty and equipment, net$23.00 KCommon stock, par value $0.0001 per share; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 63,330,747 and 54,485,518 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$6.00 KAccumulated deficitAccumulated deficit−$957.57 MAccumulated other comprehensive lossAccumulated other comprehensive loss−$1.14 M
Chart details

Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
701,690,000 US dollars
Current assets
653,794,000 US dollars
Non-current assets
47,896,000 US dollars
Liabilities
454,593,000 US dollars
Current liabilities
65,818,000 US dollars
Non-current liabilities
388,775,000 US dollars
Equity
247,097,000 US dollars
Short-term investments
446,549,000 US dollars
Cash and cash equivalents
196,577,000 US dollars
Prepaid expenses and other current assets
10,668,000 US dollars
Long-term investments
30,763,000 US dollars
Other non-current assets
16,289,000 US dollars
Operating lease right-of-use assets, net
821,000 US dollars
Property and equipment, net
23,000 US dollars
Accrued expenses
57,406,000 US dollars
Accounts payable
7,589,000 US dollars
Operating lease liabilities, current
823,000 US dollars
Convertible senior notes, net
222,956,000 US dollars
Royalty obligation
91,737,000 US dollars
Senior secured term loan, net
74,060,000 US dollars
Operating lease liabilities, less current portion
22,000 US dollars
Additional paid-in capital
1,205,803,000 US dollars
Common stock, par value $0.0001 per share; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 63,330,747 and 54,485,518 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
6,000 US dollars
Accumulated deficit
negative 957,571,000 US dollars
Accumulated other comprehensive loss
negative 1,141,000 US dollars
Gross equity (calculated)
1,205,809,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Zenas BioPharma, Inc. (ZBIO) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!